Abbott Neuromodulation's Rebecca Wilkins discusses the Infinity DBS system's design and offers advice for other device developers.

Despite facing a challenging industry-wide investment climate driven by tariffs, Abbott ABT has managed to achieve an 18.8% ...

The company is also entering new markets, such as neuromodulation for treatment-resistant depression, a $1 billion opportunity. Overall, Abbott’s innovation and broad product portfolio position ...